Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,982.38
    +3,055.44 (+3.60%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Technical Stock Chart Analysis of Breakout Medical Device Company

ACCESSWIRE

Aethlon Medical (AEMD) Featured in Technical Analysis Video

Aethlon Medical Inc. (OTCBB:AEMD - News), a medical device company focused on infectious disease and cancer, has surged about 40% over the past couple trading sessions. With no fundamental news hitting the wire, the stock broke out from its prior highs on sharply higher than average volume. Investors in related companies like Achillion Pharmaceuticals Inc. (NASDAQ:ACHN - News) or Medtronic Inc. (NYSE:MDT - News) may want to keep a close eye on the stock moving forward.

In the YouTube video linked below, AllPennyStocks provides a technical overview of the price action and discusses where prices may be heading over the coming sessions.

http://www.youtube.com/watch?v=wqyllZq0TbU&feature=share&list=UUu-NwxjXywqXcn_1DPg7fkA

ADVERTISEMENT

Sign up here to receive free email updates on AEMD: http://www.emerginggrowthcorp.com/emailassets/aemd/aemd_landing.php

About Aethlon Medical Inc.

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT(TM) System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit http://www.aethlonmedical.com/.

About Emerging Growth LLC
EGC is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies.

Disclosure
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx